The FRAXA Research Foundation has awarded a $100,000 grant to fund a research project that will test Bowen’s FX Therapeutics’ experimental protein-replacement therapies for fragile X syndrome in mice. The newly funded research will be conducted in the laboratory of Devin Binder, MD, PhD, a professor at the…
Discussion
Being a caregiver for someone with fragile X syndrome requires navigating intense emotional, physical, and financial demands, a new review study highlights. Based on these findings, researchers are calling for more proactive efforts to support caregivers of people with fragile X. The study also explores how factors like demographics and…
Fragile X syndrome is a genetic condition associated with cognitive impairment, learning and behavioral challenges, and several physical features. Learn more about the disease here.
Fragile X is caused by mutations in the fragile X mental retardation 1 (FMR1) gene, located in the X chromosome. Learn more about what causes the disease here.
Symptoms differ in severity and occurrence among patients. Life expectancy for fragile X patients is generally normal. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
